NCT01083264 - Relative Bioavailability, Transdermally Administered EE and GSD, 3 Applications Sites | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

October 31, 2009

Primary Completion Date

May 31, 2010

Study Completion Date

May 31, 2010

Conditions

Contraception

Interventions

DRUG

Gestodene/EE Patch (BAY86-5016)

Transdermal Patch, 0.55mg Ethinylestradiol + 2.1mg Gestodene, 4x7 days patch wearing period, patch-free interval of 7 days, application site: buttocks

DRUG

Gestodene/EE Patch (BAY86-5016)

Transdermal Patch, 0.55mg Ethinylestradiol + 2.1mg Gestodene, 4x7 days patch wearing period, patch-free interval of 7 days, application site: arm

DRUG

Gestodene/EE Patch (BAY86-5016)

Transdermal Patch, 0.55mg Ethinylestradiol + 2.1mg Gestodene, 4x7 days patch wearing period, patch-free interval of 7 days, application site: abdomen

Trial Locations (1)

13353

Berlin